This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Anti-Yo (also called PCA-1, APCA-1, or Type I) antibody is present in the sera and CSF in patients with gynecologic or breast cancers and paraneoplastic cerebellar degeneration (PCD). Immunohistochemistry revealed the anti-Purkinje cell antibody in a patient with PCD associated with ovarian cancer. [1] Cunningham et al. [2] reported that this antibody recognized 62-kd and 34-kd bands on an immunoblot of human Purkinje cell extracts. Tsukamoto et al. [3] reported four patients with PCD associated with uterine or ovarian cancer whose sera labeled the cytoplasm of Purkinje cells and other neurons in the CNS and recognized a 52-kd band on an immunoblot of rat cerebellar homogenates. Using this serum, Sakai et al. [4] identified the DNA sequence of the gene encoding the corresponding antigen (PCD17). On the other hand, Fathallah-Shaykh et al. [5] identified the DNA sequence of the gene encoding the Yo antigen using the antibody from a PCD patient that recognized 62/34-kd bands …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Alert Me
Recommended articles
Absence of antibodies to non-NMDA glutamate-receptor subunits in paraneoplastic cerebellar degeneration
Guidelines on the detection of paraneoplastic anti-neuronal-specific antibodies
Autoantibodies Against the Purkinje Cell Protein RGS8 in Paraneoplastic Cerebellar Syndrome
Standardized test for anti-Tr/DNER in patients with paraneoplastic cerebellar degeneration